This technology is a radiosensitizer and safely improves the effectiveness of radiation therapy. It is expected to solve the longtime fundamental problem the radiation therapy has, which is it does not work well for large sized tumor.
More than 1,000 patients with various solid tumors have been treated by the radiation therapy with KORTUC added-on as investigator initiated clinical research in Japan. Currently, the GCP based clinical trial is underway in the UK with the leadership of Institute of Cancer Research. The Phase 1 trial finished and its outcome has been published online on the Red Journal. The Phase 2 trial for locally advanced breast cancer is on-going.